参考文献：
［1］LIZAOLA B,BONDER A,TRIVEDI H D,et al.Review article:the diagnostic approach and current management of chylous ascites［J］.Aliment Pharmacol Ther,2017,11:l-9.
［2］RUNYON B A,HOEFS JC,MORGAN TR.Ascitic fluid analysis in malignancyrelated ascites［J］. Hepatology,1988,8:1104-1109.
［3］TSAUO J,SHIN J H,HAN K,et al.Transjugular intrahepatic portosystemic shunt for the treatment of chylothorax and chylous ascites in cirrhosis:a case report and systematic review of the literature［J］.J Vasc Interv Radiol,2016,27:112-116.
［4］ROMERO S,MARTIN C,HERNANDEZ L,et al. Chylothorax in cirrhosis of the liver: analysis of its frequency and clinical characteristics［J］.Chest,1998,114:154-159.
［5］MA,BIETENBECK A,SCHULZ C,LUPPA PB. Establishment of triglyceride cut-off values to detect chylous ascites and pleural effusions［J］.Clin Biochem.2017,50:134-138.
［6］ALMAKDISI T,Massoud S,Makdisi G.Lymphomas and chylous ascites: review of the literature［J］. Oncologist,2005,10:632–635.
［7］BERZIGOTTI A,MAGALOTTI D,COCCI C,et al. Octreotide in the outpatient therapy of cirrhotic chylous ascites:a case report［J］. Dig Liver Dis ,2006,38:138–142.
［8］ZUCKERMAN E,LANIR A,SABO E,et al.Cancer antigen 125:a sensitive marker of ascites in patients with liver cirrhosis［J］.Am J Gastroenter ol,1999,94:1613-1618.
［9］LEE E W,SHIN J H,KO H K. Lymphangiography to treatpostoperative lymphatic leakage:a technical review［J］.Korean J Radiol,2014,15:724–732.
［10］刘奎亮，孙宇光.肝硬化合并乳糜性腹水34 例临床特点分析［J］.中华消化杂志，2014，34（2）：96-99.
［11］AI-BUSAFI S A,GHAIL P,DESCHÊ NES M,et al.Chylous ascites: evaluation andmanagement［J］. ISRN Hepatol,2014:1-10.
［12］LOPEZ-GUTIERREZ J C ,TOVAR J A.Chylothorax and chylous ascites:management and pitfalls［J］.Semin Pediatr Surg.2014,23:298-302.(https://www.daowen.com)
［13］ILHAN E,DEMIR U,ALEMDAR A,et al.Management of high-output chylous ascites after D2-lymphadenectomy in patients with gastric cancer:a multicenter study［J］.J Gastroinest Oncol,2016,7:420-425.
［14］BERZIGOTTI A,MAGALOTTI D,COCCI C,et al.Octreotide in the outpatient therapy of cirrhotic chylous ascites:a case report［J］.Dig Liver Dis,2006,38:138-142.
［15］TALLURI S K,NUTHAKKI H,TADAKAMALLA A,Chylous ascites［J］. NAm J Med Sci,2011,3:438–440.
［16］ZHOU D X,ZHOU H B,WANG Q.The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis［J］.Dig DisSci,2009,54:1783-1788.
［17］PAN W,CAI S Y,LUO H L,et al.The application of nutrition support in conservative treatment of chylous ascites after abdominal surgery［J］.Ther Clin Risk Manag.2016,12:607-612.
［18］KOZAKI K,ILNUMA M,TAKAGI T,et al.Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis［J］.Ther Apher Dial,2016,20:376-382.
［19］TETSUYA ITO.Single center experience of Cell-free and concentrated ascites reinfusion therapy in malignancy related ascites［J］.Therapeutic Apheresis and Dialysis.2014,18（1）:87-92.
［20］KOICHI KOZAKI.Cell-free and concentrated ascites reinfusion therapy for decompensated liver cirrhosis［J］.Therapeutic Apheresis and Dialysis,2016,20（4）:376–382.
［21］BUREAU C,THABUT D,OBERTI F,et al.Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites［J］.Gastroenterolo gy,2017,152:157-163.
［22］JASON T.SALSAMENDI MD.Transjugular intrahepatic portosystemic shunt for chylous ascites in a patient with recurrent cirrhosis following liver transplantation［J］.Radiology Case Reports,2017,3:84–86.
（黎环 林勇 林春 潘晨）